Ann: Imugene Corporate Presentation, page-117

Great webinar, just finished.

Yuman is sounding extremely confident about CF33 being a "universal platform" for attacking all cancer types - through the OnCARlytics tech. It can be modified to force cancers to express any required target protein - matching it with any new targeted cancer therapy.

He is also sounding very confident about the Vaxinia trial - confirms again that it is "killing cancer" and changing the tumour micro-environment so that the immune system sees and attacks the cancer as well. Confirms also that the FDA has allowed them to accelerate the original dosage regime for the Check-vacc trial.

In response to a question he confirms that he expects IV administration to be effective. The partnership with RenovoRx is simply to expand options for treatment of "hard to reach" cancer types - and specifically Pancreatic Cancer. He went on to confirm that he believes Intra-peritoneal administration will also be effective, as per the recent pre-clinical studies.

The share price may look discouraging - but the science and the speed at which the science is progressing are all "buy" signals for me.

Cheers

Dave